Last Updated on July 16, 2026 by Dr. Bhagat
JOURNAL METRICS·Updated June 2026
JCI Insight Impact Factor 2025
JCI Insight Impact Factor 2025 is 6.8 (Q1, Medicine, Research & Experimental, SCIE). Since its launch in 2016, this gold open-access journal from the American Society for Clinical Investigation has become a trusted venue for clinically relevant basic and translational biomedical research.
ASCI OPEN ACCESSThe Society Publisher Model
JCI Insight occupies a distinctive position in the biomedical publishing ecosystem. Unlike commercial publishers, it is published by the American Society for Clinical Investigation (ASCI), a nonprofit honor society of physician-scientists founded in 1908. This society pedigree gives the journal a credibility that purely commercial open-access titles struggle to match. The 2025 Impact Factor of 6.8, while not in the stratosphere of Nature or Cell journals, represents genuine Q1 standing in the highly competitive Medicine, Research & Experimental category.
The journal’s gold open-access model ensures that all published research is immediately and freely available, meeting the requirements of Plan S, NIH Public Access Policy, and other major funder mandates. The CiteScore of 13.0, nearly double the two-year IF, indicates that JCI Insight papers accumulate substantial citations over the four-year Scopus window, a pattern typical of clinically relevant research that informs subsequent translational studies and clinical investigations.
FULL METRICSJCI Insight Data Overview
| Metric | Value | Notes |
|---|---|---|
| Impact Factor (2025) | 6.8 | JCR 2025; Q1 Medicine |
| CiteScore | 13.0 | Scopus 2025 |
| SJR | 2.917 | SCImago 2025 |
| h-index | 140 | Lifetime |
| ISSN | 2379-3708 | ASCI |
| Publisher | ASCI (self-published) | Nonprofit society |
| Established | 2016 | 9 years |
| Category | Medicine, Research & Experimental | JCR Q1 |
| Access Model | Gold Open Access | Immediate, free |
| APC | $5,000 (non-members) | ASCI members may receive discounts |
COMPARISONJCI Insight vs Related Journals
| Journal | 2025 IF | Publisher | Focus |
|---|---|---|---|
| JCI Insight | 6.8 | ASCI | Translational medicine |
| Journal of Clinical Investigation | 13.6 | ASCI | Flagship clinical research |
| Science Translational Medicine | 15.6 | AAAS | Translational science |
| Cell Reports Medicine | 14.0 | Cell Press | Translational medicine |
| EBioMedicine | 9.7 | Lancet/Elsevier | Clinical research |
Key Takeaways
- 2025 IF: 6.8 (Q1 Medicine) — strong for a society-published open-access journal.
- Gold open-access model ensures immediate free access, compliant with all major funder mandates.
- APC of $5,000 is substantially lower than Nature/Cell portfolio journals.
- CiteScore 13.0 confirms clinical relevance drives extended citation accumulation.
- Self-published by ASCI, a nonprofit honor society established in 1908.
FREQUENTLY ASKEDFAQs
What is the JCI Insight Impact Factor for 2025?
6.8, Q1 in Medicine, Research & Experimental.
Is JCI Insight a good journal?
Yes. With a Q1 ranking and ASCI society backing, it is a respected venue for translational biomedical research. The 6.8 IF places it solidly in the upper tier of open-access medicine journals.
How does it differ from JCI?
JCI (IF 13.6) is the ASCI’s flagship with higher selectivity. JCI Insight offers a broader acceptance scope while maintaining rigorous peer review and clinical relevance standards.
What is the APC?
$5,000 USD for non-ASCI members. Member discounts may apply.
Is it fully open access?
Yes. All articles are gold open access, deposited in PubMed Central immediately upon publication.
